ClinicalTrials.gg
CompletedNCT03892902Updated Oct 31, 2019

A Clinical Study to Assess Next-day Driving Performance Following Administration of ACT-541468 in Middle-aged and Elderly Subjects

A Phase 1 interventional study of ACT-541468 and Zopiclone 7.5 mg in Healthy, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Netherlands. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-31.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Oct 2019, 7 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Study summary

A clinical study to assess next-day driving performance following evening administrations of ACT-541468 in middle-aged and elderly subjects

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.

Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General criteria:

  • Signed prior to any study-mandated procedure.
  • Male and female subjects aged between 50 and 80 years (inclusive) at Screening.
  • Women of must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day 1 pre-dose of each treatment period. They must consistently and correctly use a highly effective method of , be sexually inactive, or have a vasectomized partner.
  • Women of non-childbearing potential (i.e., , XY genotype, Turner syndrome, uterine agenesis).

Study-specific criteria

  • Subject has a valid driving license for more than 5 years, has driven at least 3000 km/year on average in the past 2 years.
  • Normal visual acuity (corrected or uncorrected).

Exclusion criteria

Exclusion Criteria:

General criteria:

  • Pregnant or lactating women.
  • Any known factor or disease that might interfere with treatment compliance, study conduct, or interpretation of the results.
  • History or presence of rhythm disorders
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.

Study-specific criteria:

  • Current or previous diagnosis of insomnia-related disorder according to the version 5 (DSM-5) criteria.
  • History of alcoholism, drug abuse, or regular use of sedative drugs or hypnotics within 3 years prior to Screening.
  • History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of more than 21 units or an average daily intake of more than 3 units (males), or defined as an average weekly intake of more than 14 units or an average daily intake of more than 2 units (females). One unit is equivalent to a half-pint (approx. 250 mL) of beer or 1 measure (25 mL) of spirits or 1 glass (125 mL) of wine.
  • Modified Swiss Narcolepsy Scale total score \< 0 at Screening or history of narcolepsy or cataplexy.
  • Activities that disturb the circadian rhythm (e.g., working night shift, travelling across 3 time zones) within 2 weeks before (each) study treatment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Treatment A (50 mg ACT-541468)

    1 tablet of ACT-541468 50 mg + 1 tablet of ACT-541468 matching placebo + zopiclone matching placebo administered in the evening on Days 1-4 of Treatment Period A.

    Drug: ACT-541468 · Other: Placebo

  • Experimental
    Treatment B (100 mg ACT-541468)

    2 tablets of ACT-541468 50 mg + zopiclone matching placebo administered in the evening on Days 1-4 of Treatment Period B.

    Drug: ACT-541468 · Other: Placebo

  • Experimental
    Treatment C (7.5 mg zopiclone)

    2 tablets of ACT-541468 matching placebo + 1 capsule of zopiclone 7.5 mg administered in the evening on Days 1 and 4 of Treatment Period C. In the evenings of Days 2 and 3, subjects will receive placebo (i.e., 2 tablets of ACT-541468 matching placebo + zopiclone matching placebo).

    Drug: Zopiclone 7.5 mg · Other: Placebo

  • Experimental
    Treatment D (placebo)

    2 tablets of ACT-541468 matching placebo + zopiclone matching placebo administered in the evening on Days 1-4 of Treatment Period D.

    Other: Placebo

Interventions

  • Film-coated tablet for oral use at a dose strength of 50 mg.

  • Over-encapsulated to maintain blinding.

  • OtherPlacebo

    Matching to maintain blinding.

06

What researchers measure

Primary outcomes

  1. Pharmacodynamic endpoint: Driving performance as measured by the SDLB (difference from placebo, cm) using the Green Dino driving simulator - Day 2

    SDLP = standard deviation of the lateral position

    Time frame: On Day 2 at 9 hours post dose. Duration of the test: 1 hour

  2. Pharmacodynamic endpoint: Driving performance as measured by the SDLB (difference from placebo, cm) using the Green Dino driving simulator - Day 5

    SDLP = standard deviation of the lateral position

    Time frame: On Day 5 at 9 hours post dose. Duration of the test: 1 hour

07

Study locations

1 site
  • Centre for Human Drug Research
    Leiden, 2333, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Oct 2019, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2019
First posted
Mar 27, 2019
StartActual
Mar 25, 2019
Primary completionActual
Oct 10, 2019
CompletionActual
Oct 10, 2019
Last update
Oct 31, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03892902
Responsible party
Sponsor
First posted
Mar 27, 2019
Start date
Mar 25, 2019
Primary completion
Oct 10, 2019
Completion
Oct 10, 2019
Last update
Oct 31, 2019

Study contacts

Clinical Pharmacologist
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Daridorexant · Zopiclone

Start the discussion